These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34656132)

  • 1. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
    Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
    J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.
    Qu J; Qi TT; Qu Q; Long WM; Chen Y; Luo Y; Wang Y
    Infect Drug Resist; 2022; 15():1205-1218. PubMed ID: 35345474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria.
    Yu LL; Shi XP; Huang JF; Gong Y; Cui CX; Wang T
    J Clin Pharm Ther; 2022 Oct; 47(10):1563-1569. PubMed ID: 35670240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.
    Lu Q; Zhu HH; Li GH; Qi TT; Ye LJ; Teng XQ; Qu Q; He GF; Qu J
    Front Med (Lausanne); 2021; 8():620885. PubMed ID: 33634151
    [No Abstract]   [Full Text] [Related]  

  • 5. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
    Simon V; Viswam A; Alexander PS; James E; Sudhindran S
    Indian J Pharmacol; 2023; 55(4):229-236. PubMed ID: 37737075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.
    Cai Y; Leck H; Tan RW; Teo JQ; Lim TP; Lee W; Chlebicki MP; Kwa AL
    Antibiotics (Basel); 2020 Jul; 9(8):. PubMed ID: 32726974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB.
    Wang J; Shah BK; Zhao J; Xiong J; Wang C; Xie S
    BMC Infect Dis; 2023 May; 23(1):351. PubMed ID: 37231342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections.
    Wu XL; Long WM; Lu Q; Teng XQ; Qi TT; Qu Q; He GF; Qu J
    Front Pharmacol; 2022; 13():672543. PubMed ID: 35571125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study.
    Lima EM; Cid PA; Beck DS; Pinheiro LHZ; Tonhá JPS; Alves MZO; Lourenço ND; Santos RQ; Asensi MD; Marques JA; Bandeira CS; Rodrigues CAS; Gomes Junior SCS; Gomes MZR;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):132. PubMed ID: 32795380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study.
    Hu Y; Li D; Zhang G; Dai Y; Chen M; Jiang H; Cui W
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):875-884. PubMed ID: 38443737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia.
    Qiao L; Zuo W; Yang Y; Liu X; Wang Q; Yu J; Wu J; Xu T; Jiang J; Zhang B; Long Y
    Int J Antimicrob Agents; 2023 Aug; 62(2):106880. PubMed ID: 37301311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
    Liu S; Wu Y; Qi S; Shao H; Feng M; Xing L; Liu H; Gao Y; Zhu Z; Zhang S; Du Y; Lu Y; Yang J; Chen P; Sun T
    Crit Care; 2023 Jun; 27(1):232. PubMed ID: 37312218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections.
    Xia GL; Jiang RL
    BMC Infect Dis; 2021 Oct; 21(1):1034. PubMed ID: 34607561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
    Ting SW; Lee CH; Liu JW
    J Microbiol Immunol Infect; 2018 Oct; 51(5):621-628. PubMed ID: 28732563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort.
    Bezerra CLPAM; Dos Santos EL; Oliveira MS; Dias MBS; Levin AS; Freire MP; Boszczowski I; Salomão MC
    Clin Infect Dis; 2023 Jul; 77(Suppl 1):S62-S69. PubMed ID: 37406048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey.
    Karaaslan A; Soysal A; Altinkanat Gelmez G; Kepenekli Kadayifci E; Söyletir G; Bakir M
    J Hosp Infect; 2016 Jan; 92(1):67-72. PubMed ID: 26601601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.